When does a non-Swiss medical device or IVD manufacturer need a Swiss Authorized Representative, and what does that role actually require once a product is on the Swiss market? Swissmedic’s guidance is specific on a few points: the CH-REP’s name and address must sit next to the CH-REP symbol on the label, that address must allow genuine contact, and device registration in swissdamed becomes mandatory from 1 July 2026.
How complaints, field actions and documentation actually move between manufacturer, representative, importer and distributor is left largely to the parties to work out themselves. That gap between appointing a representative and running a working compliance arrangement is where many manufacturers underestimate the task. This piece is written for regulatory affairs and quality leaders at non-Swiss manufacturers planning to supply Switzerland, and for the operations teams responsible for labeling, supply chain and post-market surveillance once a device is on Swiss shelves. It separates what Swissmedic’s CH-REP and economic-operator guidance actually specifies — under the Medical Devices Ordinance (MedDO, SR 812.213) and the Ordinance on In Vitro Diagnostic Medical Devices (IvDO, SR 812.219) — from the practical choices manufacturers still need to make on top of that framework.
What a Swiss Authorized Representative is (and what it is not)
A Swiss Authorized Representative is the entity a foreign manufacturer designates to act on its behalf in Switzerland for regulatory purposes. The obligation sits within MedDO and IvDO, which Swissmedic describes as setting out requirements and responsibilities for operators across the medical devices supply chain. Swissmedic has also published a dedicated information sheet, MU600_00_016e, covering the obligations of economic operators active in Switzerland — including the authorised representative, the importer and the distributor.
It is worth being precise about what the role is not. A CH-REP is not a distributor, and not simply an address printed on a label to satisfy a formality. Many manufacturers already hold an authorised representative mandate for the EU market, where MDR Article 11 requires a manufacturer not established in a Member State to designate a sole authorised representative before placing a device on the Union market. Switzerland’s requirement sits in a separate piece of legislation — MedDO and IvDO — so the Swiss appointment is generally treated as its own arrangement rather than an extension of the EU one, even where the same organisation ends up performing both roles.
The Swiss regulatory landscape in one page
Many manufacturers find the Swiss framework recognisable if they already operate under EU MDR or IVDR, since both systems address similar categories of economic operator. That familiarity has limits, though: Switzerland runs its own national device database, swissdamed, and Swissmedic has aligned its design with EUDAMED so that economic operators can largely reuse device data already prepared for the European system. There is, however, no technical interface between swissdamed and EUDAMED. Swissmedic cannot import or synchronise data from the EU database automatically, so uploading device data to swissdamed is a distinct, active step rather than a byproduct of EU compliance work.
The timeline matters for planning. Registration of economic operators in Switzerland has been in place since 26 November 2021 and has been accessible within swissdamed since August 2024. Registration of devices, systems and procedure packs themselves becomes mandatory from 1 July 2026, with a transition period running to 31 December 2026, following an amendment to the IvDO dated 20 November 2024. Manufacturers planning a Swiss launch over the next two to three years should treat these dates as fixed planning anchors rather than distant deadlines, particularly where portfolio size makes manual data entry impractical.
Swissmedic’s FAQ on swissdamed also settles a point manufacturers frequently ask about: a foreign manufacturer is not required to register itself in Switzerland, but it must appoint an authorised representative. The registration obligation and the representation obligation are distinct, and the second does not disappear just because the first does not apply to the manufacturer directly.
Beyond appointment: what the mandate must actually enable
Appointing a representative is a legal act, documented through a mandate. What that mandate is worth in practice shows up less in the signed letter and more in what it allows the representative to actually do day to day. A reasonable design choice, though not spelled out in the ordinances themselves, is to specify access to technical documentation on request, a defined channel for receiving and forwarding complaints, and clarity on when the representative is authorised to respond to Swissmedic directly rather than escalating every query back to the manufacturer first. These details are left to manufacturers and representatives to agree between themselves, and they matter most exactly when something needs to move quickly.
This is where a Swiss authorized representative (CH-REP) stops being a formality and becomes an operational interface. Swissmedic ties the role directly to the label — the representative’s name and address must appear next to the CH-REP symbol — but a requirement of that kind only holds up if the party behind the address is actually reachable and resourced to respond, not simply listed there. A mandate built to satisfy the labeling line alone, without agreed response times or document-sharing arrangements, is, in our reading, likely to reveal its limits the first time a complaint needs a fast answer.
Separately, Swissmedic issues a CHRN — a Swiss registration number — to manufacturers, authorised representatives, importers and persons who assemble systems or procedure packs established in Switzerland, under Article 55 MedDO and Article 48 IvDO. The CHRN is used specifically to register these economic operators; it is not used for device-level registration. The two identifiers are not interchangeable, and conflating them risks confusion in swissdamed records further down the line.
Post-market surveillance: where execution starts to matter
Swissmedic’s information sheet on obligations for authorised representatives, importers and distributors sets out the role each party plays. It does not set out a step-by-step sequence for how a complaint should move internally once a Swiss customer, distributor or facility reports an issue — who logs it first, how quickly it reaches the manufacturer’s quality system, and who decides whether escalation is needed. That sequencing is left to the parties themselves to define.
A written understanding of who receives a complaint first, what information must travel with it, and within what timeframe it should reach the manufacturer can, in our view, reduce the risk of informal routing — a complaint forwarded ad hoc to whoever happens to handle the EU side — breaking down precisely when timing matters most. Keeping technical documentation and post-market surveillance records genuinely retrievable, rather than theoretically available somewhere in a shared system, is a related point worth testing before Swissmedic actually requests something on short notice.
Field corrective actions: practical considerations, not a documented checklist
Translating general economic-operator obligations into a working field-action process for Switzerland is left to manufacturers and their representatives to design on their own; Swissmedic’s guidance does not prescribe a sequence. A few design choices seem worth settling in advance rather than improvising under pressure, based on how these roles typically interact. Deciding ahead of time who holds authority to initiate a corrective action — without waiting on a cross-timezone email thread to confirm it — can remove a source of delay. Keeping lot and serial data, together with customer records, reconciled between the manufacturer, the importer and the distributor can make it easier to identify an affected population quickly rather than reconstructing it after the fact. Agreeing in advance how a notice will reach Swiss customers, and making sure the manufacturer, the representative and the distributor are not each sending a slightly different version of the same message, is a basic precaution worth putting in writing rather than assuming it will sort itself out. None of this replaces a documented regulatory requirement; it is a working structure, not a standard Swissmedic specifies in these terms.
UDI, swissdamed and labeling governance
Swiss manufacturers, persons who assemble systems and procedure packs, and authorised representatives must register their devices — or, in the case of authorised representatives, the devices they are mandated to cover — in swissdamed. Swissmedic offers three registration routes: a manual online editor, XML upload using the EUDAMED GET DEVICE/POST DEVICE format, and a machine-to-machine exchange through a REST API using JSON. Manufacturers with larger portfolios may find the API or XML route considerably more manageable than manual entry once device counts move past a handful of items, though the ordinance itself does not mandate one route over another.
Labeling governance around the CH-REP symbol is more specific than many manufacturers expect, and here the guidance is explicit rather than advisory. Swissmedic requires that the name and address of the authorised representative appear directly adjacent to the CH-REP symbol, and that the address genuinely enable contact to be established — a P.O. box number, an email address or a telephone number alone is explicitly stated as not sufficient. There is no fixed rule on the relative size of the symbol or the name, but Swissmedic requires both to be clearly legible to the naked eye, which in practice means checking the artwork at actual packaging scale rather than trusting a digital proof. Where harmonised standards exist for a given symbol, it must conform to them; where no such standard exists for the area concerned, Swissmedic explicitly accepts use of the symbol alone, without an accompanying explanation in the product documentation. Manufacturers who prefer not to use the symbol at all may instead write “CH authorised representative,” “CH-REP,” or “Authorised representative for Switzerland” directly on the label. Swissmedic also makes the official symbol available for download in AI, EPS, JPG and PNG formats, which removes any justification for an approximated reproduction.
Change control deserves a separate mention because labeling updates rarely stay isolated. A change triggered by a Swiss requirement — for instance, an updated representative address following a change of mandate — needs to move through document control, supplier approval and artwork sign-off like any other regulated change, with enough lead time to avoid a packaging scramble against a shipment deadline. Manufacturers managing multi-market packs sometimes absorb the Swiss-specific line into an existing multilingual panel rather than creating a dedicated Swiss SKU, which can reduce complexity if planned early enough in the artwork cycle — though this remains a packaging strategy choice, not a regulatory mandate.
Interfaces that make or break compliance
None of the mechanisms above function well in isolation. A manufacturer, its CH-REP, an importer and one or more distributors each hold a piece of the compliance picture, and the arrangement works only if responsibilities are mapped explicitly rather than assumed. Swissmedic’s own information sheet on obligations for authorised representatives, importers and distributors exists precisely because this division of labour is not self-evident from the ordinance text alone; it describes roles, but the day-to-day coordination between the parties still has to be designed by them.
Defining who owns a complaint once it is logged, who signs off internally on a vigilance submission before it reaches Swissmedic, and who simply needs to be informed afterwards can remove a fair amount of friction later, in our view. The same logic applies to agreeing, in writing, what data fields accompany a complaint when it changes hands and within what timeframe — informal email chains lose traceability over time in ways that are difficult to reconstruct during an audit. Quality agreements between the parties can help align expectations on CAPA ownership, audit rights and record retention — governance questions that sit outside what MedDO and IvDO specify directly, but that shape how smoothly things go if one of these points is ever tested. Time zone coverage and availability during Swiss public holidays are not addressed in Swissmedic’s guidance either; manufacturers based outside Europe may want to settle that question explicitly before assuming continuity of response.
Selecting a CH-REP by capability, not address
Given the above, the practical test for a CH-REP arrangement is less about whether a Swiss address exists and more about whether the representative can demonstrate competence in handling complaints, coordinating a field action and managing documentation across languages. Scale also matters: a representative handling a single product family is likely to operate differently from one managing a broad portfolio spanning Class I devices through to IVDs, each carrying its own registration and reporting nuances within swissdamed. Auditability may be one of the more informative signals available to a manufacturer, even though it is not something Swissmedic evaluates directly — a representative able to show a clear evidence trail of how a past complaint or field action was handled offers more assurance, in our assessment, than one offering only general reassurances.
Swissmedic’s September 2024 communication to all registered authorised representatives and importers, asking them to verify products against the transitional provisions for legacy devices, is a useful illustration of why a passive representative is a liability. Representatives able to confirm product status quickly were, in our reading, demonstrating the kind of operational readiness the role implies; a representative unable to answer that request promptly may struggle just as much when a real field action arises.
A suggested 30-60-90 day planning framework
None of this is prescribed by Swissmedic in these exact terms, but a phased approach, while not mandated, can make the rollout more manageable than trying to resolve everything at once. In the first thirty days, the priority is the mandate itself: finalising its scope, mapping roles across manufacturer, CH-REP, importer and distributor, agreeing a data exchange format, and running a labeling gap assessment against the CH-REP symbol requirements described above. Between days thirty-one and sixty, attention can shift to integrating post-market surveillance procedures into a shared working process and formally bringing Swiss importers or distributors into the complaint-handling chain. The final stretch, from day sixty-one to ninety, is best spent testing the arrangement rather than just documenting it — running a mock complaint through the full chain, checking that technical documentation can genuinely be retrieved on request, and feeding whatever friction surfaces back into the process before a real incident forces the issue.
Frequently asked questions
When is a Swiss Authorized Representative required? Non-Swiss manufacturers placing medical devices or IVDs on the Swiss market generally need to appoint a CH-REP under MedDO and IvDO. Swissmedic’s own guidance confirms that a foreign manufacturer is not required to register itself in Switzerland, but it must appoint an authorised representative.
Which Swiss laws define CH-REP obligations? The Medical Devices Ordinance (MedDO, SR 812.213) and the Ordinance on In Vitro Diagnostic Medical Devices (IvDO, SR 812.219) set out requirements and responsibilities for operators in the supply chain, including the authorised representative, importer and distributor.
What must appear next to the CH-REP symbol on the label? The representative’s name and address, positioned directly adjacent to the symbol. The address must enable contact to actually be established; a P.O. box number, an email address or a telephone number alone is explicitly stated as not sufficient.
Are there size requirements for the CH-REP symbol? No relative size is defined for the symbol or the name, but both must be clearly legible to the naked eye on the finished packaging.
Can manufacturers use text instead of the symbol? Yes. Swissmedic permits writing “CH authorised representative,” “CH-REP,” or “Authorised representative for Switzerland” directly on the label instead of using the graphic symbol.
Where can the official CH-REP symbol be downloaded? Swissmedic makes the symbol available on its CH-REP webpage in AI, EPS, JPG and PNG formats for use in packaging artwork.
What happened in September 2024 regarding legacy devices? Swissmedic contacted all registered authorised representatives and importers, drawing their attention to the transitional provisions for legacy devices and asking them to verify their products accordingly.
Treat CH-REP as part of a working Swiss compliance system
The publicly available Swissmedic guidance referenced here is precise about labeling, registration identifiers and the existence of an authorised representative — and largely silent on how day-to-day coordination between manufacturer, representative, importer and distributor should actually run. That silence is not an invitation to improvise. The appointment itself is a documented legal step; what protects a manufacturer’s standing with Swissmedic afterward is the working arrangement built on top of it — how a complaint moves, how clearly device data sits in swissdamed, and how reliably the CH-REP symbol on the label matches what the regulator expects to see adjacent to it. Manufacturers that design this deliberately, rather than inheriting it by default from whoever signed the mandate first, are likely to find Swiss market access considerably less eventful than the alternative.